Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

3
Is The Bottom In For Celgene?

2018-08-14 seekingalpha
Celgene Corporation (CELG) has had a less than ideal past 10 months. Hitting highs in early October 2017 of $147.17, the stock fell to $74.13 in May 2018. A 50 percent drop, or a 50 percent pop, is standard for many of the smaller biotechs I cover, but not normally, the domain of a $60B biopharmaceutical giant like CELG. A lot of the factors that led to the drop of CELG are in the past now, and the focus of this article isn't to dwell on those.
CELGZ 524816 ARNA RDY NATCOPHARM CELG RCPT MS

0
Dr Reddy#39;s eyeing European market for cancer drug

2018-08-13 moneycontrol
Natco Pharma today said its co-development and marketing partner Dr Reddys Laboratories Ltd has filed an application with the European Medicines Agency for marketing a cancer drug in Europe.
RDY NATCOPHARM 524816

0
Natco Pharma Limited - Press Release

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

0
Natco Pharma Q1 net profit up 93% to Rs 181 crore

2018-08-08 moneycontrol
Drug firm Natco Pharma today reported a 93.27 percent rise in its consolidated net profit to Rs 181.1 crore for the quarter ended June 30 mainly on account of robust sales.
NATCOPHARM 524816

0
Natco Pharma Limited - Dividend

2018-08-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

0
Natco Pharma Limited - Record Date

2018-08-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

0
Cipla, Indian Bank, HCC, Lupin, 8K Miles results

2018-08-07 thehindubusinessline
Over 175 companies including 8K Miles, 20 Microns, AB Capital, Asahi Songwon, Balrampur Chini, BEML, BPCL, Blue Star, Cipla, City Union Bank, EID Parry, Emami Infra, Forbes, Future Consumer, Goodyear, Greenply, HCC, HPCL, Hikal, Hindustan Motors, IVP, Indian Bank, Indian Hume, Jamna Auto, Kanoria Chem, Lakshmi Electrical, Lupin, Natco Pharma, NALCO, NMDC, Phoenix, PNB Housing, Siemens, Thermax, Trent and UFO Moviez will declare their April-June results on Tuesday.
HNDNF INDIANB 532210 HINDALCO NATCOPHARM CUB 524816 532814 500500 HINDMOTORS 500440

0
Natco Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

5
Celgene: Fears Are Overplayed

2018-07-10 seekingalpha
The stock is cheap providing the ability for the company to continue reducing the share count at a 10% rate.
GILD JUNO NATCOPHARM 524816 CELG

29
Market Live: Sensex falls 300 pts, metals lose shine; Europe falls 1% amid trade tensions

2018-07-02 moneycontrol
Europe Update: Shares in Europe opened sharply lower as investors question the stability of the German government and wider trade links between the European Union and the US.
BAJAJ-AUTO BHRYY 500325 524816 RELIANCE IDBI TCHQY ICLQY 532977 BHRQY 532755 500470 NATCOPHARM 534816 RIGD 500477 INFRATEL 500570 BHARTIARTL TATAMOTORS RLNIY ASHOKLEY 500116 VOD VOD TATAPOWER 532822 AKLD TECHM 532454 506022 TTST VODPF TATASTEEL TATLY PRAKASH IDEA 500102 TPCL 500400 BALLARPUR AKLS TTM

0
Natco Pharma stock rises 3% post launch of anti-HCV drug in India

2018-07-02 moneycontrol
Natco Pharma share price jumped as much as 3 percent in morning on Monday after the launch of drug that is used for the treatment of Hepatitis C, in India.
NATCOPHARM 524816

0
Natco Pharma Limited - Press Release

2018-07-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...